JP2024031736A - ブレインフォグの症状緩和及び治療用の機能性食品 - Google Patents
ブレインフォグの症状緩和及び治療用の機能性食品 Download PDFInfo
- Publication number
- JP2024031736A JP2024031736A JP2022197677A JP2022197677A JP2024031736A JP 2024031736 A JP2024031736 A JP 2024031736A JP 2022197677 A JP2022197677 A JP 2022197677A JP 2022197677 A JP2022197677 A JP 2022197677A JP 2024031736 A JP2024031736 A JP 2024031736A
- Authority
- JP
- Japan
- Prior art keywords
- functional food
- ginkgo biloba
- symptoms
- biloba extract
- brain fog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004556 brain Anatomy 0.000 title claims abstract description 27
- 208000024891 symptom Diseases 0.000 title claims abstract description 22
- 235000013376 functional food Nutrition 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 239000009429 Ginkgo biloba extract Substances 0.000 claims abstract description 23
- 229940068052 ginkgo biloba extract Drugs 0.000 claims abstract description 23
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims abstract description 23
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 13
- 235000001785 ferulic acid Nutrition 0.000 claims description 13
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 13
- 229940114124 ferulic acid Drugs 0.000 claims description 13
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 13
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 13
- -1 terpene lactone Chemical class 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 9
- 229930184727 ginkgolide Natural products 0.000 claims description 9
- 235000007586 terpenes Nutrition 0.000 claims description 9
- 241000711573 Coronaviridae Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 208000020016 psychiatric disease Diseases 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims description 4
- 208000014644 Brain disease Diseases 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- KABCFARPAMSXCC-JXMROGBWSA-N (e)-3-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]prop-2-enoic acid Chemical compound CC(C)=CCC1=CC(\C=C\C(O)=O)=CC(CC=C(C)C)=C1O KABCFARPAMSXCC-JXMROGBWSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims description 2
- 206010060860 Neurological symptom Diseases 0.000 claims description 2
- 206010037180 Psychiatric symptoms Diseases 0.000 claims description 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- KABCFARPAMSXCC-UHFFFAOYSA-N artepillin C Natural products CC(C)=CCC1=CC(C=CC(O)=O)=CC(CC=C(C)C)=C1O KABCFARPAMSXCC-UHFFFAOYSA-N 0.000 claims description 2
- 235000013793 astaxanthin Nutrition 0.000 claims description 2
- 239000001168 astaxanthin Substances 0.000 claims description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 2
- 229940022405 astaxanthin Drugs 0.000 claims description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims description 2
- 150000001851 cinnamic acid derivatives Chemical class 0.000 claims description 2
- 229920002770 condensed tannin Polymers 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 claims description 2
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 claims description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000018192 pine bark supplement Nutrition 0.000 claims description 2
- 229940106796 pycnogenol Drugs 0.000 claims description 2
- 230000000451 tissue damage Effects 0.000 claims description 2
- 231100000827 tissue damage Toxicity 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000025721 COVID-19 Diseases 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 238000010586 diagram Methods 0.000 abstract description 2
- 210000005036 nerve Anatomy 0.000 abstract description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 11
- 244000194101 Ginkgo biloba Species 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 235000008100 Ginkgo biloba Nutrition 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010002022 amyloidosis Diseases 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 108010070324 lumbrokinase Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- YXHVCZZLWZYHSA-UHFFFAOYSA-N (Z)-6-[8-pentadecenyl]salicylic acid Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-UHFFFAOYSA-N 0.000 description 1
- NGBBVGZWCFBOGO-UHFFFAOYSA-N 3,4-Methylenedioxyamphetamine Chemical compound CC(N)CC1=CC=C2OCOC2=C1 NGBBVGZWCFBOGO-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- 241001495098 Lumbricus rubellus Species 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FPUXKXIZEIDQKW-MFJLLLFKSA-N ginkgolide A Natural products O=C1[C@H](C)[C@@]2(O)[C@@H](O1)C[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H](C(C)(C)C)C4 FPUXKXIZEIDQKW-MFJLLLFKSA-N 0.000 description 1
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 description 1
- FPUXKXIZEIDQKW-VKMVSBOZSA-N ginkgolide-a Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13C[C@@H]1OC(=O)[C@@H](C)[C@]21O FPUXKXIZEIDQKW-VKMVSBOZSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
新型コロナ患者の場合、ある統計によれば、軽症から回復した患者でさえ、その8割以上が、ブレインフォグの症状と思われる「脳のモヤモヤ感」「頭がボーっとする」「注意力散漫」「集中力欠如」「認知障害」「倦怠感」などの症状を訴えている。
具体的な組成割合としては、1錠あたり、プラズマローゲン0.3mg、ルンブロキナーゼ(ルンブルスクルベルス乾燥粉末)30mgが挙げられ、フェルラ酸については4.3mg添加したことが記載されている。
薬剤A:「フェルラ酸」=103mg、「プラズマローゲン」=1.5mg、ルンブルキナーゼ150mg。
薬剤B:「フェルラ酸」=103mg、「プラズマローゲン」=1.5mg、「イチョウ葉エキス」=180mg。
薬剤C1:「フェルラ酸」=103mg、「プラズマローゲン」=1.5mg、ルンブルキナーゼ120mg、「イチョウ葉エキス」=140mg。
薬剤C2:「フェルラ酸」=103mg、「プラズマローゲン」=1.5mg、ルンブルキナーゼ150mg、「イチョウ葉エキス」=180mg。
いずれの薬剤の摂取によって患者の状態が悪化したケースはなかった。グループ1、2、3において、ブレインフォグが改善されたかどうかが明確でない状態が多く見受けられた。それに対し、グループ4では明確にブレインフォグが改善された患者が多く、薬剤C2が、有意にブレインフォグの症状改善に効果を発揮したといえる。
また、薬剤の薬理動態や作用機序などについては、確認できなかったが、4剤を投与するだけでなくルンブルキナーゼとイチョウ葉エキスの量を記憶力改善や集中力改善に有効とされる量よりも多くすることで、ブレインフォグ患者の症状が大きく緩和されることが確認できた。
Claims (6)
- ルンブルキナーゼ、イチョウ葉エキス、プラズマローゲン及びフェルラ酸の4剤を混合してなることを特徴とするブレインフォグの症状緩和及び治療用の機能性食品。
- 請求項1に記載の機能性食品において、1回の摂取量の構成が、ルンブルキナーゼは150mg以上、イチョウ葉エキスは180mg以上、フェルラ酸は103mg、プラズマローゲンは1.5mgとすることを特徴とするブレインフォグの症状緩和及び治療用の機能性食品。
- 請求項1に記載の機能性食品において、前記イチョウ葉エキスは、ギンコライドとテルペンラクトンを含み、ギンコライドの精製度は24%以上、テルペンラクトンの精製度は6%以上であることを特徴とするブレインフォグの症状緩和及び治療用の機能性食品。
- 請求項1に記載の機能性食品において、前記イチョウ葉エキスは、ギンコライドとテルペンラクトンを含み、ギンコライドの精製度は27%以上、テルペンラクトンの精製度は7%以上であること特徴とするブレインフォグの症状緩和及び治療用の機能性食品。
- 請求項1に記載の機能性食品において、前記機能性食品はブレインフォグの症状緩和及び治療に加え、以下の症状緩和及び治療にも用いられることを特徴とするブレインフォグの症状緩和及び治療用の機能性食品。
コロナ後遺症としての精神的な疾患、血管内の炎症、ADHDを含むヒトの精神疾患、精神障害、脳疾患由来の精神症状および神経症状、仕事や学習における集中力欠如、スポーツ選手の組織損傷。 - 請求項1に記載の機能性食品において、前記機能性食品は、ルンブルキナーゼ、イチョウ葉エキス、プラズマローゲン及びフェルラ酸の4剤以外に以下のもののうち少なくとも1つが混合されていることを特徴とするブレインフォグの症状緩和及び治療用の機能性食品。
L-α-グリセリルホスホリルコリン、アスタキサンチン、レシチン、ジオスゲニン、ホワイトクルクミン、タキシフォリン、ピロロキノリンキノン、ビタミンB群、ビタミンC、Co-Q10、桂皮酸誘導体アルテピリンC、DHA、EPA、オメガIII脂肪酸、ホスファチジルセリン、βラクトリン、ビンマカイナー、フラボノイ
ド類およびピクノジェノールなGABA。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022134929 | 2022-08-26 | ||
JP2022134929 | 2022-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2024031736A true JP2024031736A (ja) | 2024-03-07 |
Family
ID=90105589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022197677A Pending JP2024031736A (ja) | 2022-08-26 | 2022-12-12 | ブレインフォグの症状緩和及び治療用の機能性食品 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2024031736A (ja) |
-
2022
- 2022-12-12 JP JP2022197677A patent/JP2024031736A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021266209B2 (en) | Theacrine-based supplement and method of use thereof | |
US9763971B2 (en) | Improving recognition | |
RU2368385C2 (ru) | Применение комплексов гинкго для усиления когнитивных функций и снижения умственного утомления | |
US10201553B1 (en) | Composition of natural products for improved brain functioning | |
Hadley et al. | Medicinal herbs: a primer for primary care | |
JP2008174512A (ja) | 起床時疲労感改善用組成物 | |
Talbott et al. | Astaxanthin supplementation reduces depression and fatigue in healthy subjects | |
KR20030091971A (ko) | 항-고혈압 제제로서의 카로티노이드 | |
US20110195058A1 (en) | Cardiovascular support supplement and compositions and methods thereof | |
US10668121B2 (en) | Dietary supplements for treating ADHD and related disorders | |
Chan et al. | " At least it's natural...." Herbs and dietary supplements in ADHD | |
JP2024031736A (ja) | ブレインフォグの症状緩和及び治療用の機能性食品 | |
JP3243668U6 (ja) | 哺乳類の痴ほう症の症状緩和及び治療用の機能性食品 | |
JP3243668U (ja) | 哺乳類の痴ほう症の症状緩和及び治療用の機能性食品 | |
Ayati et al. | Advances in treatment of mild cognitive impairment (MCI) and dementia: A review of promising non-pharmaceutical modalities | |
Ocasio et al. | Natural remedies recommended for the management of oral health | |
Chang et al. | Vitamins and complementary therapies used to treat Alzheimer’s disease | |
US10004757B1 (en) | Oral supplement | |
Massey | Effectiveness of ginkgo biloba in memory disorders | |
JP2006348001A (ja) | 冷え症改善剤および機能性食品 | |
Kapoor et al. | Nutraceuticals in the management of Parkinson’s disease and dementia | |
Tripathi | Herbal memory enhancer: A review | |
Kure | Cognitive health | |
Mullaicharam et al. | Evidence-based practice of Ginkgo biloba in brain health: A review | |
Zessin | Alternative and Complementary Treatments for Extrapyramidal Symptoms, Schizophrenia, and Bipolar Disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20221226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230104 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230512 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230512 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230621 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231215 |